KRAS and neoplasm: Prior research has also characterized KRAS mutant CRC as having limited cytotoxic T cell infiltration, reduced T helper 1 responses, and reduced INF-gamma signaling, generating an overall immunosuppressive tumor microenvironment phenotype, which correlates with our finding of increased KRAS mutations in the subgroup with a suppressed TIME [48,49].